MedTrace Logo

CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms

NCT03566446 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-07-13

No results posted yet for this study

Summary

A phase-I-first in man study in patients with calreticulin(CALR)-mutant MPN by vaccinating with exon 9 mutated peptide with the adjuvant Montanide ISA-51 to monitor safety and toxicity and the immunological response to vaccination.

Conditions

  • Myeloproliferative Neoplasm, Unclassifiable
  • Essential Thrombocythemia
  • Myelofibrosis

Interventions

BIOLOGICAL

CALRLong36 peptide

200 ug CALRLong36 peptide in water mixed with 500ul montanide

Sponsors & Collaborators

  • Inge Marie Svane

    lead OTHER

Principal Investigators

  • Jacob H Grauslund, MD · Center for Cancer Immune Therapy, Denmark

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-20
Primary Completion
2020-02-20
Completion
2021-04-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03566446 on ClinicalTrials.gov